chrisvoncsefalvay/vaers-outcomes huggingface dataset:
11-6-2021:  1st dose I had a sore arm and swelling down the arm to my hand, some nausea periodically but seemed to be OK 11-27-2021:  2nd dose, within 20 minutes left side of my neck had a bit of swelling - Pharmacist provided Benadryl continued to take through the evening on Saturday.   11-28-2021:  Sunday completely fatigued and through the night stiffness in my left side set in through my entire neck, back, throat and pain all along my collarbone, swelling in the collarbone and along with swelling in the vein.  Pain across the chest.  All issues were contained on my left side.  Nothing on the right side. 11-29-2021:  Woke to extreme fatigue, slow breathing, weakness and swelling was getting worse... pain was increasing.  Went to the hospital midday around 12P to 1PM.  Had to wait to see a doctors for close to 3 hours.  Started in Emergency moved to ICU details below 11-30-2021:  Released from ICU.   12-1-2021:  Recovering at home from all the treatments.  Recommended to take benadryl, as needed and follow-up
Throat itching, chills, severe dizziness, low bp,  headache within 10 minutes of receiving  shot.    Over the next 6 hours started having pain in upper chest and congestion .
36 hrs after injection, had erythema, heat, itching, swelling above elbow, at least 3" below injection site.  Felt fine after injection. Continues with erythema 3 days post injection, decreased head, itching, swelling
Dtap given 4/25/06 on 4/26/06 slight erythema at injection site, then on 4/27/06 more inflammation and much more erythema, heat with firm borders 10x12 cm, TX'D with OMNICEF 150mg BIS X 10D for cellulitis RXN to DTaP.
Very mild fatigue? It felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though . . . maybe because the allergen (spike) was more specific?; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old  patient of unknown gender received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8729) via an unspecified route of administration in the arm right on 01Apr2021 at 17:45 (at the age of 73-year-old) as a single dose for COVID-19 immunization. Medical history included chronic fatigue. Concomitant medications were not reported. The patient previously received bacitracin zinc, neomycin sulfate, polymyxin b sulfate( NEOSPORIN) and pneumococcal vaccine(MANUFACTURER UNKNOWN) on an unknown date and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021, the patient experienced very mild fatigue which felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though maybe because the allergen (spike) was more specific. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the events very mild fatigue which felt pure and pleasant, compared with usual allergy and/or emotional fatigue, though maybe because the allergen (spike) was more specific was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Information has been received from a RN concerning a 12 month old female who on 01/27/99 was vaccinated with a dose of varicella virus vaccine live (Lot # 625470/0315H).  In approximately Feb 1999, "shortly after the immunization (with in a month perhaps)", the child developed a rash around the site of injection described as "bumpy varicella-like rash" that was confined in a 2x2 inch area on the child's thigh. The duration of the rash was one year and between ages 2 and 3 it was believed that she was "OK". It was noted that every year around the anniversary of her original immunization, the child developed a rash in the same confined area of her thigh "as when she was a baby". "The rash goes away after scabbing up". The child had not been seen by a physician for this condition. In 2000, "at age 3", the child developed a case of chickenpox. There was no prescription drug required for treatment. There was no product quality complaint involved. At the time of this report, the child was 5 years of age. The reporter also mentioned that inon 08/06/03, the child received MMRII and on 08/08/03, "presented with rash again" (WAES # 0308UA01150).  Additional information has been requested.
Patient feels pain when arm is moved in any direction. Requires a pillow to support arm when sleeping due to pain.
at first i was fine and the next morning i noticed my whole bottom lip was swollen. Lasted about 2 days after taking Benadryl.
This spontaneous case was reported by a pharmacist (subsequently medically confirmed) and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second vaccine outside of 42 day window from first dose) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for an unknown indication. The patient's past medical history included No adverse event (No reported medical history). On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second vaccine outside of 42 day window from first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second vaccine outside of 42 day window from first dose) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. This report refers to a case of product dose omission issue for mRNA-1273, lot # 006M20A, with no associated AEs.; Sender's Comments: This report refers to a case of product dose omission issue for mRNA-1273, lot # 006M20A, with no associated AEs.
Patient threw up with 3-5 min after getting 1st booster of pfizer. He then turned very pale, having blurred vision, sweating. His forehead was very cold when touched. Patient fainted on the bench for a few seconds. Patient got moderna as his first and his 2nd dose, he was fine.
About 10-15 min after vaccination patient began to experience left side facial numbness and tingling to include her tongue and cheek
Hospitalization for worsening COVID symptoms  on dates 6/26/2022-  6/28/2022 .  Treated with Multivitamin, ascorbic acid 1000mg daily, vitamin D3  25mcg daily, and zinc sulfate 50mg PO daily
After vaccine, the next day I got up and my feet were red and swollen from ankle down with small blisters on top of my feet that lasted from 3/10 through 3/14, it's not 100% gone but most is gone today. I went to the Urgent Care Clinic and the doctor said it will go away, I took Benedryl. They tested me for Coronavirus and it was negative.
This case was reported by a pharmacist and described the occurrence of alopecia of scalp in an adult female patient who received hepatitis B vaccine recombinant.  On an unspecified date, the patient received a dose of Engerix-B.  At an unspecified time following the administration of Engerix-B, the patient experienced alopecia of scalp and alopecia of eyebrows.  The patient was seen at a physician's office.  The events were unresolved.   The reporting pharmacist considered the events to probably be related to vaccination with Engerix-B.
stiffness in her neck; pain neck; rash all over her neck/rash has gone on to her face; breaking out in hives through out her body; lip is swollen; bumps underneath her lip; rash is going inside her mouth; This is a spontaneous report from a contactable consumer (patient). This 36-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number ER8731, expiration date 31Jul2021, on 14Apr2021 at single dose for COVID-19 immunization. Family history included lupus, COPD, diabetes which her mother had and she basically got it so she could be around her mother. Concomitant medication was none. The patient had the shot last Wednesday (14Apr2021) and then by Saturday (17Apr2021) she had severe neck pain and stiffness in her neck, she couldn't move her neck. The pain was ongoing. She had no rash on her arm but she had rash all over her neck and she went to the doctor and they gave her a steroid shot because they thought maybe it could be something different. She had the steroid and she still breaking out in hives through out her body. They gave her a steroid shot on Monday (19Apr2021) but the rash had gone on to her face, her lip was swollen, there were bumps underneath her lip and the rash was going inside her mouth and even though she got the steroid shot she was still breaking out in new hives. She said she was going to have to go and go back to work she thought this was going to be quick and it was not. She did not have the name of the steroid injection or have a lot expiration to provide. They also gave her Naproxen for the stiffness in her neck and a muscle relaxer. The outcome of stiffness in her neck, pain neck and rash all over her neck/rash has gone on to her face was not resolved. The outcome of other events was unknown.  No follow-up attempts are possible. No further information expected.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site redness in a female patient who received FLULAVAL QUADRIVALENT (batch number 93T79, expiry date June 2016). On 9th October 2015, the patent received FLULAVAL QUADRIVALENT .5 ml. On 9th October 2015, 10 hrs after receiving FLULAVAL QUADRIVALENT, the patient experienced injection site redness and injection site warmth. On an unknown date, the outcome of the injections site redness and injection site warmth were not recovered/not resolved. The reporter considered the injection site redness and injection site warmth to be related to FLULAVAL QUADRIVALENT. Additional details were provided as follows: The patient experienced red and warm area around the injection site, which was 2 inches in diameter. The healthcare professional did not have date of birth of the patient.
Bicep became swollen 3-4 " away from injection site and red. Swelling into forearm.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 76-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 12Sep2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 76 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Type 2 diabetes" (unspecified if ongoing). Patient had no known allergies. Concomitant medication(s) included: METFORMIN; LISINOPRIL; ALLOPURINOL; GEMFIBROZIL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19, which included Paxlovid from 26Nov2022 to 01Dec2022.  The information on the batch/lot number for [BNT162B2, BNT162B2 OMI BA.4-5] has been requested and will be submitted if and when received.
Pt stated her vaccination was administered lower than normal. She received both immunizations in the same arm as per her request. She reported headache, swelling and body aches.
red neck rash around the neck still after 12 days, itches and burns, benadryl did not help
-Edema, redness, warm to touch at site - approx 6 inch area. Temp up to 101.8 F. - TYLENOL & BENADRYL given. - MOTRIN & ice prescribed also.
Blood clots; Felt extremely ill; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (Blood clots) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Cancer and Autoimmune disorder.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced THROMBOSIS (Blood clots) (seriousness criterion medically significant) and MALAISE (Felt extremely ill). At the time of the report, THROMBOSIS (Blood clots) and MALAISE (Felt extremely ill) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
unbearable pain; Fever; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 20-JUN-2023, the patient received Shingles vaccine. In JUN-2023, an unknown time after receiving Shingles vaccine, the patient experienced pain (Verbatim: unbearable pain) and fever (Verbatim: Fever). The outcome of the pain and fever were not reported.   It was unknown if the reporter considered the pain and fever to be related to Shingles vaccine.     It was unknown if the company considered the pain and fever to be related to Shingles vaccine.   Additional Information: GSK receipt date: 21-JUN-2023 This case was received by a consumer via interactive digital media. Yesterday (day before reporting) he/she got vaccinated which was an unbearable pain due to which got fever, but it does not compare to what suffer with shingles, he/she would not prefer to go all through this again and as there were people who would repeat it.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. On 25-NOV-2013, the patient was vaccinated in the upper right arm with the first dose of PNEUMOVAX 23 (dose, strength and lot # were not provided). There was no concomitant medication reported. Pharmacist stated post vaccination with PNEUMOVAX 23, the patient developed swelling of the right arm that extended down to her right elbow (approximately in the 2013). Patient's present status was reported as "fine now". There was not treatment given to the patient. Additional information is not expected.
Mouth sores and bumps on tongue and lower gums. Burning, sore and more aggravated when eating and drinking. Slight irritation of tonsils, throat and uvula. Duration: 8/15/2020 to date. Still have sores on lover gum and unable to wear my dental partial.
sick; had a cold when she went back for the second dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program.  A 87 year-old female patient received bnt162b2 (BNT162B2), administration date 26Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "sick"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "had a cold when she went back for the second dose".  Additional Information: The reporter was the patient's daughter. The patient had a cold when she went back for the second dose. The community center where she went to get the vaccine wouldn't let her get it. They also wouldn't reschedule the vaccine until she gets over the cold. The reporter was asking how does she reschedule for her mother.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
COVID-19; COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34-year-old female patient (not pregnant) received bnt162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2023, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included paxlovid from 10Sep2023 to 14Sep2023.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The evening of the injection patient began to have welts on trunk of body, arms & legs. Welts continued x 7 days when patient came in for second injection.  Second injection not give due to previous reaction.  Patient took p.o. Benadryl. Patient did not report reaction until she came in for second injection.
lethargic fever stomach was hot to touch bumpy small like bites on injection site, they got crusty didn't feel well headache
Next day lost hearing in left ear and getting worse; Feels pressure and ringing in her ear.; Feels pressure and ringing in her ear./ ringing was worsening; Next day lost hearing in left ear and getting worse; This is a spontaneous report from a contactable consumer (patient).   A 65-year-old female patient received the 2nd dose of bnt162b2 (BNT162B2, Batch/lot # EL3246) at single dose at right arm on 03Feb2021 16:30 for covid-19 immunisation, because of her age and she had asthma and to protect her elderly and sick parents.  Medical history included ongoing ongoing asthma all of her life, ongoing tinnitus 10 years approximately, allergies to everything, environmental allergies, medication, food allergies, contact allergies, ongoing fibromyalgia a decade, ongoing gastrooesophageal reflux disease (GERD) 10-15 years. Family history: father had bladder cancer and going through bowel resection surgery, mother was immunocompromised with polymyalgia rheumatica. Concomitant medication included gabapentin (GABAPENTIN) 200 mg, 1x/day at bedtime) for Fibromyalgia, famotidine (PEPCID) OTC dose in morning and night FOR GERD.   After vaccination, towards 04Feb2021 evening, she started losing hearing in her left ear. That was late afternoon. It started with some pressure, and some loss of hearing. By 05Feb2021 it got worse. So she gave herself Sudafed because she was thinking it was normal allergies. By 06Feb2021, it wasn't better. The Sudafed did not seem to help. She went to the Urgent care on 06Feb2021, who told her to go to ENT. She has an ENT appointment on 09Feb2021. The Urgent care prescribed her a short dose of prednisone by mouth 10mg twice a day. She has looked, and not find loss of hearing as a side effect. She hasn't called the doctor yet. The hearing loss has persisted or worsened. It is not constant all day long, but it is there all day long. As of on 09Feb2021, it was pretty bad. On 04Feb2021 she was also experiencing ear ringing. It was a high pitched ring in the same ear. She had tinnitus in both ears, but it was usually low. This one since the pressure started building in her ear, the ringing was louder and bigger. The ringing was worsening. The outcome of events was not recovered.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a elderly female patient who received SHINGRIX (batch number 9XC39, expiry date 30th January 2020) for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced injection site pain, injection site itching and injection site erythema. On an unknown date, the outcome of the injection site pain was recovering/resolving and the outcome of the injection site itching and injection site erythema were unknown. It was unknown if the reporter considered the injection site pain, injection site itching and injection site erythema to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported but it could be 69 or 70 year. The healthcare professional (HCP)reported that following a dose of SHINGRIX, the patient experienced a sore arm, redness and some itching at the injection site. Within 2 days, the intensity of all event were decreasing.
Fever up to 103.2. Chills, fatigue, joint pain, headache, dizziness, muscle aches
At 1500 medic made contact with client who was sitting in observation status post 2nd dose Pfizer COVID vaccine. Client reported feeling lightheaded and had tingling in fingers and on tongue. She stated she had the symptoms after her first dose of Pfizer COVID vaccine received 04/02/21 (LOT: EW0150, Expiration 07/31/2021). Client stated she spoke with her primary care provider who advised her to receive second dose of vaccine and to be aware symptoms may reappear with second dose. Medic noted that client was alert and oriented to time, space, person, and situation (CAOx4) and had positive pulse, motor, sensory and capillary refill (PMSC) responses. At 1508 baseline vitals signs were obtained with client sitting in zero gravity chair: Blood pressure (BP): 110/80, Respiratory Rate (RR): 14, Heartrate (HR): 69, pupils were equal, accommodating, round and reactive to light (PEARRL), Skin: normal color for ethnicity, warm and dry. At 1510 client was reassessed for lightheadedness, client stated she was no longer lightheaded but still felt tingling in hands and new onset of "having to think about swallowing". Client denied shortness of breath (SOB), headache, chest pain, nausea, vomiting, blurry vision, sensation of throat closing, or mouth and lips swelling. Client was CAOx4. At 1512 50 mg Benadryl oral suspension administered to client. Client continued drinking water without any difficulty and denied dysphagia. At 1518 second set of vitals taken while sitting: BP 112/60, HR: 66, RR 14, PEARRL, reassessed symptoms and client stated improvement of tingling sensation, positive PMSC, client rated symptoms a 4/10 and continued to deny SOB, headache, chest pain, nausea, vomiting, blurry vision, and throat closing. Client stated she felt very thirsty and a second bottle of water was given to client. Client advised to stay longer in observation. At 1529 third set of vitals taken while client standing: BP 116/80, HR 68, RR 14, PEARRL, CAOx4, client negative for orthostatic pressures. At 1542 client released from care after a total 1 hour observation. She was able to stand and walk on her own accord away from the site with a steady gait.
Hypotension after 5 minutes of flu vaccine. Patient was observed in the next 15 minutes until the blood pressure normalized.
pt recvd vax & devel a gen varicella-like rash; 2 siblings also recvd vax w/varicella that day & did not develop a rash;further info from reporter stated that was not his pt;
RIGHT ARM RED AND SWOLLEN DOWN TO THE ELBOW. CHILD NOT ABLE TO LIFT THE ARM. COMPLAINS OF PAIN AT SIGHT OF INJECTION.